Childhood cancers trials in United Kingdom
157 trials · From ClinicalTrials.gov and EU CTIS (euclinicaltrials.eu), checked 10 Nov 2026. Ask the study team whether a trial fits you.
Phase 4RecruitingTrial-stage medicine
Asciminib Roll-over Study
- Where
- London, Oxford
- Age
- 7 years to 100 years
- People
- 347 worldwide
- Run by
- Novartis Pharmaceuticals
See details and how to joinNCT04877522EU 2023-507557-16-00Registry updated 2026-11-09
Phase 2RecruitingTrial-stage medicine
177Lutetium-DOTATATE in Children With Primary Refractory or Relapsed High-risk Neuroblastoma
- Where
- Glasgow, London
- Age
- 18 months to 64 years
- People
- 24 worldwide
- Run by
- Jakob Stenman
See details and how to joinNCT04903899EU 2023-503684-42-00Registry updated 2026-11-09
No phaseRecruitingResearch participation
PRIMER: Development of Daily Online Magnetic Resonance Imaging for Magnetic Resonance Image Guided Radiotherapy
- Where
- Sutton
- Age
- 3 years and over
- People
- 173
- Run by
- Institute of Cancer Research, United Kingdom
See details and how to joinNCT02973828Registry updated 2026-11-06
Phase 1/2RecruitingTrial-stage medicine
A Study of Neladalkib (NVL-655) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ALK Rearrangement or Activating ALK Mutation (ALKOVE-1)
- Where
- Edinburgh, London, Manchester, Sutton
- Age
- 12 years and over
- People
- 840 worldwide
- Run by
- Nuvalent Inc.
See details and how to joinNCT05384626EU 2024-514266-39-00Registry updated 2026-11-06
Phase 3RecruitingTrial-stage medicine
A Rollover Study for Participants Previously Enrolled in a Genentech and/or F. Hoffman-La Roche Sponsored Study
- Where
- Leicester, Surrey
- People
- 200 worldwide
- Run by
- Hoffmann-La Roche
See details and how to joinNCT05862285EU 2023-504263-16-00Registry updated 2026-11-06
Phase 1/2RecruitingTrial-stage medicine
A Phase 1/2 Study of Bleximenib in Participants With Acute Leukemia (cAMeLot-1)
- Where
- Cardiff, Leeds, Liverpool, London, Manchester, Oxfordshire, Plymouth
- Age
- 2 years and over
- People
- 420 worldwide
- Run by
- Janssen Research & Development, LLC
See details and how to joinNCT04811560EU 2023-506581-31-00Registry updated 2026-11-04
Phase 2RecruitingTrial-stage medicine
Belzutifan/MK-6482 for the Treatment of Advanced Pheochromocytoma/Paraganglioma (PPGL), Pancreatic Neuroendocrine Tumor (pNET), Von Hippel-Lindau (VHL) Disease-Associated Tumors, Advanced Gastrointestinal Stromal Tumor (wt GIST), or Solid Tumors With HIF-2α Related Genetic Alterations (MK-6482-015)
- Where
- Cambridge, Glasgow, London
- Age
- 12 years and over
- People
- 355 worldwide
- Run by
- Merck Sharp & Dohme LLC
See details and how to joinNCT04924075EU 2023-504853-11-00Registry updated 2026-11-03
Phase 2/3RecruitingTrial-stage medicine
Long-Term Follow-up Protocol for Participants Treated With Gene-Modified T Cells
- Where
- Leeds, London, Manchester Withington, Shirley Southampton
- People
- 1,541 worldwide
- Run by
- Celgene
See details and how to joinNCT03435796EU 2023-504201-36-00Registry updated 2026-11-02
Phase 1/2RecruitingTrial-stage medicine
Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01)
- Where
- Birmingham, Cardiff, London, Newcastle upon Tyne, Sutton
- Age
- 6 months to 25 years
- People
- 90 worldwide
- Run by
- Merck Sharp & Dohme LLC
See details and how to joinNCT06395103EU 2023-507178-41-00Registry updated 2026-10-30
No phaseRecruitingResearch participation
Met Non Small Cell Cancer Registry (MOMENT)
- Where
- Bedford, Birmingham, Bournemouth, Cardiff, Chelsea, Harrow, Huddersfield, Liverpool, London, Preston, Swindon, Torquay
- People
- 700 worldwide
- Run by
- EMD Serono Research & Development Institute, Inc.
See details and how to joinNCT05376891Registry updated 2026-10-29
Phase 1RecruitingTrial-stage medicine
Study of Lunresertib Alone or in Combination With RP-3500 or Zedoresertib (Debio 0123) in Patients With Advanced Solid Tumors
- Where
- London
- Age
- 12 years and over
- People
- 464 worldwide
- Run by
- Debiopharm International SA
See details and how to joinNCT04855656EU 2023-510063-35-00Registry updated 2026-10-28
Phase 1/2RecruitingTrial-stage medicine
Study of AZD3632 Monotherapy or in Combination With Anticancer Agents in Participants With Advanced Haematologic Malignancies With KMT2Ar, NPM1m, or Other Genotypes Associated With HOX Overexpression
- Where
- Edinburgh, London, Manchester, Newcastle
- Age
- 16 years and over
- People
- 85 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT07155226EU 2025-521299-76-00Registry updated 2026-10-23
Phase 3RecruitingTrial-stage medicine
Study of Revumenib in Combination With Intensive Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia (AML) With a NPM1 Mutation
- Where
- Aberdeen, Derby, Leicester, Lincoln, London, Oxford, Southampton, Sutton
- Age
- 12 years and over
- People
- 468 worldwide
- Run by
- Syndax Pharmaceuticals
See details and how to joinNCT07211958EU 2025-522279-27-00Registry updated 2026-10-21
Phase 3RecruitingTrial-stage medicine
A Phase 3 Study of Tabelecleucel for Participants With Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease After Failure With Rituximab or Rituximab and Chemotherapy
- Where
- Birmingham, London
- People
- 115 worldwide
- Run by
- Pierre Fabre Medicament
See details and how to joinNCT03394365EU 2024-516622-57-00Registry updated 2026-10-19
Phase 1/2RecruitingTrial-stage medicine
Study of AZD4512 Monotherapy or in Combination With Anticancer Agents in Participants With Acute Lymphoblastic Leukemia
- Where
- Bloomsbury, Manchester
- Age
- 12 years and over
- People
- 83 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT07109219EU 2025-522372-93-00Registry updated 2026-10-15
Phase 1/2RecruitingTrial-stage medicine
AZD0486 as Monotherapy in B-cell Acute Lymphoblastic Leukaemia
- Where
- London, Manchester, Surrey
- Age
- 12 years and over
- People
- 255 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT06137118EU 2023-505840-20-00Registry updated 2026-10-13
Phase 1/2RecruitingTrial-stage medicine
AZD3470 as Monotherapy or in Combination With Anticancer Agent(s) in Participants With Haematologic Malignancies.
- Where
- Manchester, Oxford
- Age
- 12 years and over
- People
- 161 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT06137144EU 2023-506747-42-00Registry updated 2026-10-13
Phase 1/2RecruitingTrial-stage medicine
Safety and Efficacy of Ponatinib for Treatment of Pediatric Recurrent or Refractory Leukemias, Lymphomas or Solid Tumors
- Where
- Glasgow, Liverpool, Sutton
- Age
- 1 year to 17 years
- People
- 70 worldwide
- Run by
- Incyte Biosciences International Sàrl
See details and how to joinNCT03934372EU 2023-509699-41-00Registry updated 2026-10-09
Phase 1RecruitingTrial-stage medicine
A Study of CD19 Targeted CAR T Cell Therapy in Pediatric Patients With Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia (B ALL) and Aggressive Mature B-cell Non-Hodgkin Lymphoma (B NHL)
- Where
- London, Manchester, Newcastle upon Tyne
- Age
- 0 years to 18 years
- People
- 30 worldwide
- Run by
- Autolus Limited
See details and how to joinNCT06173518EU 2023-506307-26-00Registry updated 2026-10-09
Phase 1RecruitingTrial-stage medicine
Phase 1, Safety and Tolerability Study of XmAb541 in Advanced Solid Tumors
- Where
- Manchester
- Age
- 15 years and over
- People
- 282 worldwide
- Run by
- Xencor, Inc.
See details and how to joinNCT06276491Registry updated 2026-10-09
No phaseRecruitingResearch participation
BEAT-Breast: Trial of DE-iPTV in Patients With Primary Breast Cancer With Brain Metastases Who Are Not Suitable for Stereotactic Radiotherapy.
- Where
- London, Oxford
- Age
- 16 years to 100 years
- People
- 42
- Run by
- Imperial College London
See details and how to joinNCT06611306Registry updated 2026-10-08
Phase 2/3RecruitingTrial-stage medicine
Safety and Efficacy of EIK1001 in Combo With Pembro Versus Placebo and Pembro as First-Line Therapy in Patients With Advanced Melanoma.
- Where
- Belfast, London, Southampton
- Age
- 18 years and over
- People
- 740 worldwide
- Run by
- Eikon Therapeutics
See details and how to joinNCT06697301EU 2024-512659-19-00Registry updated 2026-10-06
Phase 1/2RecruitingTrial-stage medicine
A Study of Patritumab Deruxtecan in Pediatric Participants With Relapsed or Refractory Solid Tumors (MK-9999-01C/LIGHTBEAM-U01)
- Where
- Birmingham, Cardiff, Newcastle upon Tyne, Sutton
- Age
- 1 month to 17 years
- People
- 50 worldwide
- Run by
- Merck Sharp & Dohme LLC
See details and how to joinNCT06941272EU 2024-518771-66-00Registry updated 2026-10-06
Phase 1RecruitingTrial-stage medicine
A Study to Assess Adverse Events and How Intravenous (IV) Pivekimab Sunirine Moves Through the Body in Pediatric Participants With Relapsed or Refractory Acute Myeloid Leukemia (AML)
- Where
- Cambridge
- Age
- 6 months to 17 years
- People
- 18 worldwide
- Run by
- AbbVie
See details and how to joinNCT07306832Registry updated 2026-10-05
Phase 1/2RecruitingTrial-stage medicine
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
- Where
- London, Newcastle upon Tyne
- Age
- 12 years and over
- People
- 300 worldwide
- Run by
- PMV Pharmaceuticals, Inc
See details and how to joinNCT04585750Registry updated 2026-10-02
All Childhood cancers trials and the map
This page is not medical advice. Talk to your doctor before contacting a trial.